PT - JOURNAL ARTICLE AU - Tahleesa J. Cuda AU - Andrew D. Riddell AU - Cheng Liu AU - Vicki L. Whitehall AU - Jennifer Borowsky AU - David K. Wyld AU - Matthew E. Burge AU - Elizabeth Ahern AU - Alison Griffin AU - Nicholas J.R. Lyons AU - Stephen E. Rose AU - David A. Clark AU - Andrew R.L. Stevenson AU - John D. Hooper AU - Simon Puttick AU - Paul A. Thomas TI - PET Imaging Quantifying <sup>68</sup>Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer AID - 10.2967/jnumed.119.233312 DP - 2020 Nov 01 TA - Journal of Nuclear Medicine PG - 1576--1579 VI - 61 IP - 11 4099 - http://jnm.snmjournals.org/content/61/11/1576.short 4100 - http://jnm.snmjournals.org/content/61/11/1576.full SO - J Nucl Med2020 Nov 01; 61 AB - At diagnosis, 22% of colorectal cancer (CRC) patients have metastases, and 50% later develop metastasis. Peptide receptor radionuclide therapy (PRRT), such as 177Lu-PSMA-617, is used to treat metastatic prostate cancer. 177Lu-PSMA-617 targets prostate-specific membrane antigen (PSMA), a cell-surface protein enriched in prostate cancer and the neovasculature of other solid tumors, including CRC. We performed 68Ga-PSMA-11 PET/CT imaging of 10 patients with metastatic CRC to assess metastasis avidity. Eight patients had lesions lacking avidity, and 2 had solitary metastases exhibiting very low avidity. Despite expression of PSMA in CRC neovasculature, none of the patients exhibited tumor avidity sufficient to be considered for 177Lu-PSMA-617 PRRT.